- Home
- OKYO
OKYO
OKYO Pharma Limited
as 07-26-2024 4:00pm EST
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
| Founded: | 2007 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 43.6M | IPO Year: | 2022 |
| Target Price: | $7.00 | AVG Volume (30 days): | 33.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.09 - $3.07 | Next Earning Date: | 08-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest OKYO Pharma Limited News
OKYO Breaking Stock News: Dive into OKYO Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
GlobeNewswire
17 days ago
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
GlobeNewswire
3 months ago
OKYO Pharma Announces Participation in May 2024 Investor Conferences
GlobeNewswire
3 months ago
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
GlobeNewswire
4 months ago
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
GlobeNewswire
4 months ago
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
GlobeNewswire
4 months ago
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
GlobeNewswire
4 months ago
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
Compare OKYO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OKYO OKYO Pharma Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.